Detalhe da pesquisa
1.
Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Cancer
; 121(7): 1056-63, 2015 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25411085
2.
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
J Clin Oncol
; 27(18): 3036-43, 2009 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-19414675